(0.23%) 5 307.75 points
(0.23%) 38 880 points
(0.33%) 18 652 points
(-0.38%) $76.70
(4.06%) $2.69
(-0.40%) $2 336.30
(-1.07%) $30.12
(-0.32%) $1 038.70
(0.02%) $0.921
(0.10%) $10.50
(0.00%) $0.785
(-0.39%) $90.08
2 days till quarter result
(tns 2024-06-05)
Expected move: +/- 10.73%
@ $35.38
Issued: 21 Mar 2024 @ 14:07
Return: -32.67%
Previous signal: Mar 20 - 11:15
Previous signal:
Return: 1.94 %
Live Chart Being Loaded With Signals
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States...
Stats | |
---|---|
Today's Volume | 786 465 |
Average Volume | 1.28M |
Market Cap | 1.96B |
EPS | $0 ( 2024-05-08 ) |
Next earnings date | ( $-1.420 ) 2024-06-05 |
Last Dividend | $0.225 ( 2014-02-04 ) |
Next Dividend | $0 ( N/A ) |
P/E | -14.89 |
ATR14 | $0.0310 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-26 | Burrell Terry-ann | Buy | 12 500 | Common Stock |
2024-04-26 | Burrell Terry-ann | Buy | 25 000 | Stock Option (Right to Buy) |
2024-04-01 | Simon Amy | Sell | 7 157 | Common Stock |
2024-04-02 | Simon Amy | Sell | 16 530 | Common Stock |
2024-04-01 | Bellon Christine | Sell | 3 401 | Common Stock |
INSIDER POWER |
---|
-11.16 |
Last 98 transactions |
Buy: 1 537 714 | Sell: 1 873 404 |
Volume Correlation
Beam Therapeutics Inc Correlation
10 Most Positive Correlations | |
---|---|
OZEM | 1 |
DFLI | 0.939 |
CRSP | 0.923 |
ORGN | 0.906 |
HLP | 0.902 |
NBBK | 0.894 |
MAMA | 0.893 |
FONR | 0.893 |
BUJA | 0.892 |
AAIDX | 0.884 |
10 Most Negative Correlations | |
---|---|
RDZN | -0.894 |
PTLO | -0.89 |
BRLSW | -0.881 |
CLMB | -0.88 |
RENB | -0.878 |
FUFUW | -0.871 |
NWGL | -0.869 |
GBLMX | -0.867 |
KITT | -0.867 |
KYTX | -0.86 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Beam Therapeutics Inc Correlation - Currency/Commodity
Beam Therapeutics Inc Financials
Annual | 2023 |
Revenue: | $377.71M |
Gross Profit: | $357.70M (94.70 %) |
EPS: | $-1.720 |
FY | 2023 |
Revenue: | $377.71M |
Gross Profit: | $357.70M (94.70 %) |
EPS: | $-1.720 |
FY | 2022 |
Revenue: | $60.92M |
Gross Profit: | $38.34M (62.94 %) |
EPS: | $-3.76 |
FY | 2021 |
Revenue: | $51.84M |
Gross Profit: | $51.84M (100.00 %) |
EPS: | $-5.77 |
Financial Reports:
No articles found.
Beam Therapeutics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.190 | 2011-11-07 |
Last Dividend | $0.225 | 2014-02-04 |
Next Dividend | $0 | N/A |
Payout Date | 2014-03-03 | |
Next Payout Date | N/A | |
# dividends | 10 | -- |
Total Paid Out | $2.16 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.6 | -- |
Div. Sustainability Score | 0.664 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
HRZN | Dividend Royal | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.373 | 1.500 | -7.47 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.0991 | 1.200 | -3.30 | -3.96 | [0 - 0.3] |
returnOnEquityTTM | -0.155 | 1.500 | -2.83 | -4.24 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.99 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.85 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.537 | 1.500 | 2.57 | 3.85 | [0.2 - 2] |
debtRatioTTM | 0.124 | -1.500 | 7.94 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -7.37 | 1.000 | -3.84 | -3.84 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.703 | 2.00 | -0.568 | -1.135 | [0 - 30] |
freeCashFlowPerShareTTM | -2.07 | 2.00 | -1.036 | -2.07 | [0 - 20] |
debtEquityRatioTTM | 0.184 | -1.500 | 9.26 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.929 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.503 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.828 | 1.000 | -5.71 | -5.71 | [0.2 - 2] |
assetTurnoverTTM | 0.265 | 0.800 | -1.564 | -1.251 | [0.5 - 2] |
Total Score | 0.664 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -14.44 | 1.000 | -1.560 | 0 | [1 - 100] |
returnOnEquityTTM | -0.155 | 2.50 | -1.819 | -4.24 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -2.07 | 2.00 | -0.691 | -2.07 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.703 | 2.00 | -0.568 | -1.135 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.144 | 1.500 | -4.30 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.385 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.51 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators